Paul Hutchinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul Hutchinson has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
A. J. Hughes
Department of Respiratory Medicine, Monash Medical Centre, Melbourne, Victoria, Australia
1 shared publication- Matthew D. Jose
Royal Hobart Hospital, Hobart, Tasmania, Australia
1 shared publication N. J. Freezer
Department of Respiratory Medicine, Monash Medical Centre, Melbourne, Australia
1 shared publicationP. D. R. Johnson
Department of Infectious Diseases, Austin and Repatriation Medical Centre, Melbourne, Australia
1 shared publicationRobert C Atkins
Department of Nephrology Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia
1 shared publicationRobert C. Atkins
1 shared publication
Latest Publications
- 28 July 2005
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 142 (1) , 132-139
Diagnosis ofMycobacterium tuberculosisinfection using ESAT-6 and intracellular cytokine cytometry
Summary: Diagnosis of infection with Mycobacterium tuberculosis (MTB) using tuberculin skin testing (TST) is often hampered by prior Bacille Calmette–Guérin (BCG) vaccination. ESAT-6 is a protein that is expressed by MTB but absent in BCG. It has been postulated that it might be useful in distinguishing MTB-specific immune responses. This study measured CD4 T cell responder frequencies specific for ESAT-6 and the TST reagent purified protein derivative (PPD) in patients with tuberculosis (n = 16), controls with non-tuberculous pneumonia (n = 8) and normal subjects (n = 7). Responses were identified using the intracellular cytokine staining technique and flow cytometry on whole blood samples, and performed blinded to the patient condition. Antigen-specific CD4 cells were defined by CD69 positivity and one or more cytokine [interleukin (IL)-2, IL-4, IL-10, interferon (IFN)-γ] and/or CD40L positivity. With ESAT-6 stimulation it was found that TB patients had significantly higher frequencies of IFN-γ and CD40L-positive CD4 T cells compared to the normal group, while no significant differences were measured with PPD stimulation. A responder frequency of 0·01% or higher for at least one of the measured cytokines/CD40L was defined as a positive response. Using this criterion to compare the two patient groups, PPD had 100% sensitivity but 0% specificity while ESAT-6 had 100% sensitivity and 88% specificity. Use of MTB-specific proteins such as ESAT-6 in combination with intracellular cytokine staining and flow cytometry has the potential to identify individuals with MTB infection.
- 28 July 2005
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 142 (1) , 132-139
Diagnosis ofMycobacterium tuberculosisinfection using ESAT-6 and intracellular cytokine cytometry
Summary: Diagnosis of infection with Mycobacterium tuberculosis (MTB) using tuberculin skin testing (TST) is often hampered by prior Bacille Calmette–Guérin (BCG) vaccination. ESAT-6 is a protein that is expressed by MTB but absent in BCG. It has been postulated that it might be useful in distinguishing MTB-specific immune responses. This study measured CD4 T cell responder frequencies specific for ESAT-6 and the TST reagent purified protein derivative (PPD) in patients with tuberculosis (n = 16), controls with non-tuberculous pneumonia (n = 8) and normal subjects (n = 7). Responses were identified using the intracellular cytokine staining technique and flow cytometry on whole blood samples, and performed blinded to the patient condition. Antigen-specific CD4 cells were defined by CD69 positivity and one or more cytokine [interleukin (IL)-2, IL-4, IL-10, interferon (IFN)-γ] and/or CD40L positivity. With ESAT-6 stimulation it was found that TB patients had significantly higher frequencies of IFN-γ and CD40L-positive CD4 T cells compared to the normal group, while no significant differences were measured with PPD stimulation. A responder frequency of 0·01% or higher for at least one of the measured cytokines/CD40L was defined as a positive response. Using this criterion to compare the two patient groups, PPD had 100% sensitivity but 0% specificity while ESAT-6 had 100% sensitivity and 88% specificity. Use of MTB-specific proteins such as ESAT-6 in combination with intracellular cytokine staining and flow cytometry has the potential to identify individuals with MTB infection.
- 31 July 2004
- Published by Elsevier in Transplant Immunology
- Vol. 13 (1) , 55-61
Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment
- 31 July 2004
- Published by Elsevier in Transplant Immunology
- Vol. 13 (1) , 55-61
Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment
- Open Access
- 1 May 2003
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (5) , 983-989
Laboratory assessment of immune function in renal transplant patients
Background. Advances in immunosuppression have made renal transplantation an effective therapy for end stage renal failure; with low rejection rates and long graft survival times. However, the major adverse consequences, infection and malignancy have not diminished. To predict this risk a score of immune competence has been developed from the simultaneous laboratory assessment of multiple parameters of immune function. Methods. The immune status of 152 transplant recipients (138 renal and 14 pancreas/renal) was assessed by measurement of lymphocyte subsets, mitogen‐induced T‐cell proliferative responses, neutrophil phagocytic capacity and reactive oxygen species (ROS) generation. A scoring system was devised based on the average number of these parameters below 10th percentile of normal. Results. The most common abnormality was B‐cell lymphopenia (85%) followed by reduced neutrophil ROS production (63% of patients), NK cell lymphopenia (50%), lymphocyte mitogen response (49%) and CD4 number (23%). The abnormalities were unrelated to the duration of immunosuppression (up to 15 years), and variable combinations of cyclosporine A, azathioprine, prednisolone and mycophenolate mofetil (MMF) (except for a consistent reduction in lymphocyte mitogen response in MMF treated patients). Retrospective comparison of infective episodes showed a significantly greater index of infections in patients with the worst score compared with a normal score. Conclusions. The data suggests that this quantification of immune function may allow assessment of the level of host immune defence reflecting the level of drug‐induced immunosuppression and thus risks of immunosuppressive complications.
- 1 May 2003
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (5) , 983-989
Open AccessLaboratory assessment of immune function in renal transplant patients
Background. Advances in immunosuppression have made renal transplantation an effective therapy for end stage renal failure; with low rejection rates and long graft survival times. However, the major adverse consequences, infection and malignancy have not diminished. To predict this risk a score of immune competence has been developed from the simultaneous laboratory assessment of multiple parameters of immune function. Methods. The immune status of 152 transplant recipients (138 renal and 14 pancreas/renal) was assessed by measurement of lymphocyte subsets, mitogen‐induced T‐cell proliferative responses, neutrophil phagocytic capacity and reactive oxygen species (ROS) generation. A scoring system was devised based on the average number of these parameters below 10th percentile of normal. Results. The most common abnormality was B‐cell lymphopenia (85%) followed by reduced neutrophil ROS production (63% of patients), NK cell lymphopenia (50%), lymphocyte mitogen response (49%) and CD4 number (23%). The abnormalities were unrelated to the duration of immunosuppression (up to 15 years), and variable combinations of cyclosporine A, azathioprine, prednisolone and mycophenolate mofetil (MMF) (except for a consistent reduction in lymphocyte mitogen response in MMF treated patients). Retrospective comparison of infective episodes showed a significantly greater index of infections in patients with the worst score compared with a normal score. Conclusions. The data suggests that this quantification of immune function may allow assessment of the level of host immune defence reflecting the level of drug‐induced immunosuppression and thus risks of immunosuppressive complications.